The name was changed to Aqualis in 2013 and subsequently to Weifa in 2014. Thus, Weifa ASA retains the title and interest in all intellectual property (IP) generated by Clavis Pharma, including the Lipid Vector Technology (LVT) and all product related IP under the LVT umbrella. Clavis Pharma originally developed a series of LVT derivatives targeting several diseases with high unmet medical need, including key oncology indications like acute myeloid leukemia (AML) and pancreatic cancer. Important patents remain in force in key markets. Currently two products have been licensed to third parties.

For further information or inquiries regarding LVT products please contact: